Keene ON - Search Results

1

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Pavord ID, et al. Among authors: keene on. Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X. Lancet. 2012. PMID: 22901886 Clinical Trial.

2

Biomarkers for severe eosinophilic asthma.

Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I. Yancey SW, et al. Among authors: keene on. J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. J Allergy Clin Immunol. 2017. PMID: 29221581 Free article. Review.

3

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.

Yancey SW, Ortega HG, Keene ON, Mayer B, Gunsoy NB, Brightling CE, Bleecker ER, Haldar P, Pavord ID. Yancey SW, et al. Among authors: keene on. J Allergy Clin Immunol. 2017 Apr;139(4):1167-1175.e2. doi: 10.1016/j.jaci.2016.08.008. Epub 2016 Oct 7. J Allergy Clin Immunol. 2017. PMID: 27726946 Free article.

4

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Ortega HG, et al. Among authors: keene on. Lancet Respir Med. 2016 Jul;4(7):549-556. doi: 10.1016/S2213-2600(16)30031-5. Epub 2016 May 10. Lancet Respir Med. 2016. PMID: 27177493 Clinical Trial.

5

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Bel EH, et al. Among authors: keene on. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199060 Free article. Clinical Trial.

6

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Ortega HG, et al. Among authors: keene on. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199059 Free article. Clinical Trial.

7

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.

Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A. Mäkelä MJ, et al. Among authors: keene on. J Infect. 2000 Jan;40(1):42-8. doi: 10.1053/jinf.1999.0602. J Infect. 2000. PMID: 10762110 Clinical Trial.

8

An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R; Losmapimod Study Investigators. Lomas DA, et al. J Clin Pharmacol. 2012 Mar;52(3):416-24. doi: 10.1177/0091270010397050. Epub 2011 Nov 16. J Clin Pharmacol. 2012. PMID: 22090363 Clinical Trial.

9

Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma.

Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Ortega H, et al. J Allergy Clin Immunol. 2015 Sep;136(3):825-6. doi: 10.1016/j.jaci.2015.05.039. Epub 2015 Jul 17. J Allergy Clin Immunol. 2015. PMID: 26194540 No abstract available.

10

Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reduction.

Keene ON. Keene ON. Pharm Stat. 2019 Jan;18(1):78-84. doi: 10.1002/pst.1909. Epub 2018 Oct 29. Pharm Stat. 2019. PMID: 30370691

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results